Login / Signup

Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.

Emily C L WongParambir S DulaiJohn K MarshallVipul JairathWalter ReinischNeeraj Narula
Published in: Inflammatory bowel diseases (2022)
Treatment with infliximab and ustekinumab among induction responders achieved 1-year CR with similar efficacy, but infliximab may confer greater benefit for endoscopic outcomes. Findings should be interpreted with caution as our analyses were unpowered.
Keyphrases
  • ulcerative colitis
  • rheumatoid arthritis
  • ultrasound guided
  • adipose tissue